Newsroom

WARSAW, Poland--(BUSINESS WIRE)--Regulatory News: CTP, Europe's largest listed developer, owner, and operator of industrial and logistics properties by gross leasable area (GLA), announces Windar Renovables will develop its second production facility in Poland with the construction of a new onshore wind turbine tower manufacturing plant at CTPark Legnica in south west Poland. CTP has leased 29,000 sqm of industrial and warehouse space to Windar Renovables for the major new facility, alongside a...

GENT, Belgium & TOKYO--(BUSINESS WIRE)--H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Europe N.V. has obtained a CE Certificate of the Lumipulse G NfL Blood assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Neurofilament light chain (NfL) in plasma and serum. “While ou...

BILBAO, Spain--(BUSINESS WIRE)--H2SITE, a technology company delivering hydrogen production and separation solutions, announces the appointment of Javier Cavada as the new Chairman of the Board of Directors. Javier joins H2SITE at a strategic phase of accelerated industrial deployment and scale-up of its hydrogen solutions. With more than 25 years of international leadership in the energy and industrial sectors, Javier brings extensive experience in industrialising complex technologies, buildin...

TAIPEI, Taiwan--(BUSINESS WIRE)--(美國商業資訊)-- 全球提供即插即用平台、協助打造與管理世界最佳 IoT 產品的 1NCE 今日宣布與全球智慧交通解決方案領導企業 光林智能（LEOTEK） 展開策略合作。本次合作旨在加速 LEOLink AI 智慧燈聯網系統（Intelligent Lighting System, ILS） 的國際部署。此外，日本 SoftBank Corp. 擔任 1NCE 在包含台灣在內之亞太地區的獨家銷售夥伴。 在 2026 Smart City Summit & Expo 展期間，合作夥伴展示一套整合 1NCE 與 LEOTEK AI 驅動管理的統一架構，使各城市可將傳統街道照明轉型為高效能的數位化網路，並實現零接觸（zero-touch）的全球部署。透過整合 1NCE 平台，LEOTEK 無需再與各地電信業者簽訂本地電信合約，即可在超過 170 個國家即時部署數千台裝置。1NCE 的軟體與連線平台成為業界的新選擇，免去繁瑣流程的 IoT 體驗。對 LEOTEK 而言，這意味著其 AI 驅動照明設備可在全球完成出貨、...

TAIPEI, Taiwan--(BUSINESS WIRE)--1NCE, the global company offering a plug-and-play platform for creating and managing the world’s best IoT products, together with its exclusive APAC sales partner SoftBank Corp., today announced a strategic collaboration with LEOTEK, a global leader in intelligent traffic solutions. The partnership aims to accelerate the international deployment of the LEOLink Intelligent Lighting System (ILS). At the 2026 Smart City Summit & Expo, the partners are showcasin...

GENT, Belgien, und TOKIO--(BUSINESS WIRE)--H.U. Group Holdings Inc. und ihre 100-prozentige Tochtergesellschaft Fujirebio Holdings, Inc. (nachstehend „Fujirebio“) gaben heute bekannt, dass Fujirebio Europe N.V. die CE-Kennzeichnung für den Lumipulse G NfL-Bluttest gemäß der Verordnung (EU) 2017/746 über In-vitro-Diagnostika-Medizinprodukte (IVDR) erhalten hat. Der CLEIA-Test (chemolumineszierender Enzymimmunassay) ermöglicht die quantitative Messung der Neurofilament-Leichtkette (NfL) im Plasma...

GENT, Bélgica e TÓQUIO--(BUSINESS WIRE)--H.U. A Group Holdings Inc. e sua subsidiária integral, Fujirebio Holdings, Inc. (doravante “Fujirebio”), anunciaram hoje que a Fujirebio Europe N.V. obteve a certificação CE para o ensaio sanguíneo Lumipulse G NfL, em conformidade com o Regulamento (UE) 2017/746 sobre dispositivos médicos para diagnóstico in vitro (IVDR). Este teste CLEIA (ensaio imunoenzimático quimioluminescente) permite a medição quantitativa da cadeia leve de neurofilamento (NfL) no...

GAND, Belgique et TOKYO--(BUSINESS WIRE)--H.U. Group Holdings Inc. et sa filiale à 100 %, Fujirebio Holdings, Inc. (ci-après « Fujirebio »), ont annoncé aujourd’hui que Fujirebio Europe N.V. a obtenu le certificat CE pour le test sanguin Lumipulse G NfL conformément au règlement (UE) 2017/746 relatif aux dispositifs médicaux de diagnostic in vitro (IVDR). Ce test CLEIA (dosage immunoenzymatique par chimiluminescence) permet la mesure quantitative de la chaîne légère des neurofilaments (NfL) dan...

比利時，根特 & 東京--(BUSINESS WIRE)--(美國商業資訊)-- H.U. Group Holdings Inc.及其全資子公司Fujirebio Holdings, Inc.（以下簡稱「Fujirebio」）今天宣布Fujirebio Europe N.V.的Lumipulse G神經元絲 (NfL) 血液檢測儀通過歐盟2017/746有關體外診斷醫療器材 (IVDR) 的規範，取得CE認證。這種CLEIA（化學發光酶免疫測定）測試可以定量測量血漿和血清中的神經元絲。 「雖然我們的檢測清單上已經有許多強效的疾病特異性生物標記，但神經元絲的加入仍象徵一項重大突破：這是我們第一次取得CE標誌的血液檢測項目，能夠為臨床醫生提供跨大層面神經系統疾病的分析。」Fujirebio Europe N.V.執行長Christiaan De Wilde說，「我們很高興能將這項檢測獻給客戶，進一步擴大我們在LUMIPULSE G平台上的全自動神經系統疾病檢測解決方案組合。我們將繼續與世界各地的機構和臨床專家合作，致力提供更早期、更便利、更完整的神經系統疾病診斷工具。」 關於NfL 神經元...

GENT, België & TOKIO--(BUSINESS WIRE)--H.U. Group Holdings Inc. en haar volledige dochteronderneming, Fujirebio Holdings, Inc. (hierna “Fujirebio”), hebben vandaag bekendgemaakt dat Fujirebio Europe N.V. een CE-certificaat heeft verkregen voor de Lumipulse G NfL-bloedtest onder Verordening (EU) 2017/746 betreffende in vitro diagnostische medische hulpmiddelen (IVDR). Deze CLEIA-test (chemiluminescente enzymimmunoassay) maakt de kwantitatieve meting van neurofilament-lichte keten (NfL) in plasma...